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Atorvastatin (ATV) is an antilipemic drug of great interest to the pharmaceutical industry. ATV does not 
appear in the monographs of Brazilian pharmacopoeia, and analytical methodologies for its determination 
have been validated. The chromatographic conditions used included: RP-18 column-octadecylsilane (250 
x 4.6 mm, 5 mm), detection at 238 nm, mobile phase containing 0.1% phosphoric acid and acetonitrile 
(35:65% v/v), flow at 1.5 mL min-1, oven temperature at 30oC, and injection volume of 10 mL. ATV 
is classified as a class II product, according to the biopharmaceutical classification system. As such, 
a dissolution test was proposed to evaluate pharmaceutical formulations on the market today, under 
the following conditions: water as a dissolution medium, 1000 mL as a volume, paddle apparatus at a 
rotation speed of 50 rpm, 80% (Q) in 15 minutes with UV spectrophotometer readings at 238 nm. In 
the pattern condition proposed as the ideal dissolution test, which appropriately differentiates amongst 
formulations, the generic product was not considered pharmaceutically equivalent; however, in other 
less differential dissolution methods, which also fall within appropriate legal parameters, this product 
could come to be regarded as generic.
Uniterms: Pharmaceutical formulations/evaluation. Atorvastatin. Drugs/dissolution test. Drugs/
qualitative analysis.
Atorvastatina (ATV) é um fármaco antilipêmico de grande interesse para a indústria farmacêutica. ATV não 
apresenta monografia na Farmacopéia Brasileira e metodologias analíticas para sua determinação foram 
validadas. As condições cromatográficas utilizadas foram: coluna RP-18-octadecilsilano (250 x 4.6 mm, 
5 mm), detecção em 238 nm, fase móvel contendo ácido fosfórico 0,1% e acetonitrila (35:65% v/v), 
fluxo de 1,5 mL min-1, temperatura do forno de 30 oC e volume de injeção de 10 mL. ATV é classificada 
como um fármaco de classe II, de acordo com o sistema de classificação biofarmacêutica (SCB). Como 
tal, um teste de dissolução foi proposto para avaliar as formulações farmacêuticas do mercado atual, sob 
as seguintes condições: água como meio de dissolução, volume de 1000 mL, aparato pá, velocidade de 
rotação de 50 rpm, 80% (Q) em 15 minutos com leituras espectrofotômetro UV a 238 nm. Na condição 
padrão proposta para o teste de dissolução, o qual seria capaz de diferenciar apropriadamente as 
formulações farmacêuticas, o produto genérico não foi considerado equivalente farmacêutico. No entanto, 
em outros métodos de dissolução menos discriminativos, que também seriam considerados apropriados 
pelos parâmetros legais, este produto pode vir a ser considerado como genérico.
Unitermos: Formulações farmacêuticas/avaliação. Atorvastatina. Fármacos/teste de dissolução. 
Fármacos/análise qualitativa.
INTRODUCTION
Lipitor®, the reference product of atorvastatin 
calcium tablets, has been the world’s top selling drug in 
2012, yielding a revenue of approximately $8 billion for 
the manufacturer Pfizer. According to the Brazilian Asso-
ciation of Generic Products, in 2008, Lipitor® sold over 
1.3 million units, representing a turnover of U.S. $85 mil-
lion, ranking third in Brazilian pharmaceutical industry 
sales (Blenkinsopp, 2003; Neuman, 2010).
Atorvastatin (ATV) is used to reduce the levels of 
lipoproteins, which are rich in cholesterol, as well as the risk 
of coronary artery disease (CAD). This is due to the inhibi-
tory action that the drug has on the hydroxymethylglutaryl-
CoA reductase (HMG-CoA reductase) enzyme which is 
important in the biosynthesis of cholesterol (Gomes, 2008).
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AT V  ( I )  h a s  a  m o l e c u l a r  f o r m u l a  o f 
C66H68CaF2N4O10.3H2O and a molecular weight of 1209.4 
g/mol. It is a white crystalline powder with a partition 
coefficient (log P (octanol/water)) of 6.36, a constant dis-
sociation (pKa) of 4.46, and a fusion of between 159.2ºC 
and 160.7oC. The drug is insoluble in aqueous solutions 
at pH ≤ 4.0; very slightly soluble in water, phosphate buf-
fer (pH 7.4), and acetonitrile; slightly soluble in ethanol; 
and very soluble in methanol (Moffat et al., 2004; Shete 
et al., 2010).
ATV has no known registration in the Brazilian 
pharmacopoeia (Brasil, 2010a), but it can be found in 
one monograph in the American pharmacopoeia (USP, 
2012). To perform a chemical analysis with secure and 
reliable results, and considering the possibility of using 
the methodology set forth by overseeing bodies, such as 
the Central Laboratories of Public Health, the validation 
of methods is of paramount importance in an attempt to 
provide evidence to support decisions and possible health 
interventions (Brasil, 2003a). For an analytical method to 
be considered officially validated, it must include suitable 
parameters, such as precision, accuracy, linearity, limit of 
detection and quantification, specificity, and robustness 
(Brasil, 2003a; ICH, 2005).
Specificity can be evaluated by analyzing drugs 
after having been submitted to stressful conditions, also 
called intrinsic or inherent stability, under the effect of 
temperature, humidity oxidation, exposure to UV light, 
and hydrolysis at different pH values (ICH, 2005; ICH , 
2003; Brasil, 2005; Silva et al., 2009).
The reliability of the analytical method by high 
performance liquid chromatography is also verified by 
the system’s suitability parameters, or “performance 
parameters”. The main parameters evaluated included: 
retention factor (k’), number of theoretical plates (N), 
resolution (Rs), and asymmetry or tailing factor (T) (Bra-
sil, 2010a; ICH, 2005). The retention factor (k’) evaluates 
the analyte’s degree of affinity with the stationary phase. 
The optimum value of k’ should be between 0.5 and 20, 
according to Snyder et al. (1997), or be larger than 2, ac-
cording to the FDA (1994) and Swartz and Krull (1998) 
(Snyder et al., 1997; FDA, 1994; Swartz; Krull, 1998). The 
number of theoretical plates (N) estimates the efficiency of 
the column upon separation of the analyte, which should 
be at least 2000 plates/column (ICH, 2005; FDA, 1994; 
Ribani et al., 2004). According to Snyder et al. (1997) and 
Swartz and Krull (1998), resolution (Rs) represents the 
parameter that quantifies the degree of separation between 
two substances, which should be greater than 1.5, whereas 
Ribani et al. (2004) report that this value must be greater 
than 2 (Snyder, 1997; Swartz, Krull, 1998; Ribani et al., 
2004). The tailing factor (T) evaluates the symmetry of 
the peak, which should have a value of 1 when the peak 
is perfectly symmetrical. T values of less than or equal to 
2 are also acceptable (Brasil, 2010a; FDA, 1994; Ribani 
et al., 2004).
The absorption of drugs from solid pharmaceutical 
forms, when administered orally, depends on their release, 
dissolution, or solubility under physiological conditions, 
as well as the drugs’ permeability through the membranes 
of the gastrointestinal tract. Due to the critical nature, the 
in vitro dissolution test may well aid in predicting the in 
vivo performance (Brasil, 2003b).
ATV presents a low solubility in aqueous mediums 
and a high permeability and is therefore classified in the 
biopharmaceutical classification system (BCS) as a Class 
II drug (Amidon et al., 2004; Benet, 2006). For this class, 
the dissolution is the rate-limiting step in absorption and in 
vitro in vivo correlation (IVIVC) is to be expected (Brasil, 
2003b; FDA, 1997).
To develop a dissolution test, one must: quantita-
tively evaluate the solubility of active ingredients in the 
physiological pH range of 1.2 to 6.8, considering the tem-
perature of 37 oC ± 1 oC; demonstrate that the dissolution 
medium is the most appropriate for the active ingredient in 
the dosage form under investigation; demonstrate that the 
apparatus, the rotation, and the filters used in the sample 
collection procedure are best suited for the active ingredi-
ent and dosage form; demonstrate the need to use anchors 
(if applicable); demonstrate the need to use of surfactants 
and the relevant amount (if applicable); demonstrate and 
justify the choice of Q value (the quantities of active ingre-
dient dissolved from the dosage units tested in percentage 
for the specified time); and justify the need for the deaera-
tion (when applicable) (Brasil, 2010b).
The dissolution profile (percent dissolved versus 
time) allows one to guide the development and opti-
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mization of pharmaceutical formulations, to monitor 
manufacturing processes, to minimize the risk of a lack of 
bioequivalence between batches, to obtain the approval of 
registration with the competent organ, to search and detect 
the influence of critical variables in the production process, 
to establish the mechanism and release kinetics, to make 
an in vitro/in vivo correlation, and to make comparative 
studies of different formulations (Anderson et al., 1998; 
Castro et al., 2005; Pillay, Fassihi, 1998; Reis, 1998).
 The dissolution profile is a comparative study 
performed with sampling at multiple times to assess 
the dissolution of a particular drug and to compare two 
formulations. Graphs are plotted, and the comparison of 
dissolution profiles of different formulations is performed 
by calculating the similarity factor (F2), according to equa-
tion 1 (Brasil, 2010b).
  (1)
where: n = number of sampling times, Rt = value of per-
centage dissolved at time t, obtained with the reference 
product; Tt = percentage value of the test product dissolved 
at time t.
According to the RDC 31/2010, two dissolution pro-
files are considered similar if the similarity factor (F2) is 
between 50 and 100. The collection samples times must be 
the same for both the generic and reference formulations, 
and the number of sampling points must be representative 
(until a plateau in the curve has been reached) and should 
have at least five sampling times. In addition, the coef-
ficients of variation for the first collection points should 
not exceed 20%, while the remaining points should not 
exceed 10% (Brasil, 2010b).
However, when the active ingredient presents a high 
solubility and the pharmaceutical formulation produces 
immediate release tablets, which present a very rapid 
dissolution for both drugs (average amount dissolved is 
no less than 85% of the labeled content expressed as per-
centage within 15 minutes). F2 factor loses its ability to 
discriminate; therefore, there is no need to calculate this 
factor. In such cases, it can be observed that the pharma-
ceutical formulations present a very rapid dissolution by 
release graphics, performing samples in times of 5, 10, 
15, 20, and 30 minutes. The coefficient of variation at 15 
minutes should not exceed 10% (Brasil, 2010b).
Another means through which to compare the dis-
solution profile is by calculating the dissolution efficiency 
(DE), introduced in 1972 by Khan and Rhodes, which is 
determined by the ratio of the percentage of the area under 
the curve (AUC), obtained from the dissolution profile, and 
by the total area of the rectangle, taken as 100% of dissolu-
tion for the same time interval. DE is calculated according 
to equation 2 (Anderson et al., 1998; Cárcamo, 1981).
  (2)
where:  = AUC at a time t, expressed in per-
centage; y100xt = area of the rectangle considering 100% 
dissolution at the same time t.
The results obtained by the F2 and DE may be 
theoretically correlated with the in vivo data, since the 
bioavailability can be determined by integrating the AUC 
of the absorption of a drug versus time (Brasil, 2003b; 
Brasil, 2010b; Anderson et al., 1998).
The aim of the present study was to develop reliable 
analytical methods to determination of atorvastatin and 
determine standard conditions for dissolution test and 
dissolution profile.
METHODS
Development, optimization, and validation of 
assay methods
Two methods of assay were used for comparison and 
definition of a more appropriate method for dosing in the 
dissolution test. These included:
1)  The determining of ATV by High Performance 
Liquid Chromatography coupled to the UV/DAD 
(HPLC/UV-DAD) detector. The chromatographic 
conditions used included: RP-18 column - octa-
decylsilane (250 x 4.6 mm, 5 mm), detection at 
238 nm, mobile phase containing 0.1% phosphoric 
acid and acetonitrile (35:65% v/v), flow at 1.5 mL 
min-1, oven temperature at 30°C, injection volume of 
10 mL, and analysis time of approximately 10 minu-
tes (Yoshida et al., 2011; USP, 2012). The samples 
were solubilized in methanol.
2)  The determining of ATV by UV spectrophotometer 
and readings at 238 nm, with solubilization of sam-
ples in water.
The methods were optimized and validated accord-
ing to Resolution n. 899/2003 and ICH Q2 (R1) guidelines, 
evaluating the following parameters: Precision in the range 
from 17.5 to 32.5 mg mL-1 in terms of repeatability and 
intermediate precision; Accuracy, intra-day and between-
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day, in the range from 17.5 to 32.5 mg mL-1; Linearity in 
the concentration range from 17.5 to 32.5 μg mL-1; Limit 
of Detection (LOD) estimated based on the ratio of 3 times 
the noise baseline and determined according to equation (3); 
and Limit of Quantification (LOQ), which was determined 
by equation (4) (Brasil, 2003a; INTERNATIONAL, 2005).
  (3)
  (4)
where: SDa is the standard deviation of the intercept with 
the Y axis of at least three calibration curves containing 
concentrations of the drug near the presumed limit; IC is 
the slope of the calibration curve.
The factors considered in determining of the Ro-
bustness in the HPLC method included: a change in the 
mobile phase composition, a variation in temperature, and 
a variation in the mobile phase flow.
To evaluate the Specificity, the stress conditions (in-
trinsic stability) of the ATV were investigated after 4 hours 
of exposure by using: heating under dry heat at 105°C; 
reflux in a water bath in pure water, in 1 M NaOH, in 1 M 
HCl, and in 3% H2O2; as well as exposure to UV light at 
254 nm (ICH, (R2), 2003; Silva et al., 2009).
Concerning the chromatographic performance, 
the parameters were calculated according to formulas 
proposed by the Brazilian Pharmacopoeia, attaining the 
retention factor (k’), the tailing factor (T), the number of 
theoretical plates (N), and resolution (Rs) between peaks 
(Brasil, 2010a).
Development of dissolution test to compare 
formulations
The dissolution test was developed according to 
national and international legislations (Brasil, 2010b). Tab-
lets of the reference drug product and of the generic drug 
product were evaluated. The first tests were performed on 
the generic product and, according to the results, the best 
conditions to test the reference product was then selected.
The formulation of the drugs used at 80 mg/dose 
included:
a) Reference Product: calcium carbonate, micro-
crystalline cellulose, lactose monohydrate, croscarmel-
lose sodium, polysorbate 80, hypromellose, magnesium 
stearate, dye opadry white®, and simethicone emulsion.
b) Generic Product: lactose monohydrate, trolamine, 
sodium starch glycolate, docusate sodium, sodium benzo-
ate, sodium stearyl fumarate, hyprolose, titanium dioxide, 
macrogol, and polysorbate 80.
The content of drugs in the pharmaceutical products 
was performed using a validated HPLC analytical method 
with standard and samples diluted at a concentration of 
20.0 mg mL-1 in methanol.
The conditions used to determine the dissolution test 
and the comparison of formulations are shown in Table I.
For each condition a dissolution profile with a sam-
pling aliquot of 15 mL was performed at time periods of 
5, 10, 15, 30, 45, and 60 minutes, with no replacement of 
the medium. These were then filtered through filter quality 
paper and subsequently diluted until reaching a theoretical 
final concentration of 32.0 mg mL-1. The absorbance of the 
solutions was measured by a spectrophotometer at 238 nm 
using the same solvent for the zero setting. The amount of 
C66H68CaF2N4O10 dissolved in the medium was calculated 
by comparing the readings of the sample solution with that 
of the standard solution at a concentration of 32.0 mg mL-1.
After obtaining the dissolution profiles and having 
plotted the graphs, the DE was also calculated. The results 
for the dissolution profile underwent an analysis of vari-
ance (ANOVA) to determine the differences in the mean 
values of two drugs (reference and generic products) at 
each time; p values of  <0.05 were considered significant. 
TABLE I - Conditions tested for dissolution profile
Condition Parameters Pharmaceutical Formulations
I
Medium: water containing 0.4% 
sodium lauryl sulfate (SLS), 1000 mL.
Paddle Apparatus, 75 rpm
Generic Product
II Medium: water, 1000 mL.Paddle Apparatus, 50 rpm. Generic Product and Reference Product
III Medium: water, 1000 mL.Paddle Apparatus, 75 rpm. Generic Product and Reference Product
IV Medium: water, 1000 mL.Basket Apparatus, 50 rpm. Reference Product
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Calculations were performed using an OriginPro8® pro-
gram (ORIGINPRO, 2007).
RESULTS AND DISCUSSION
Validation of assay methods
For the evaluated assay methods, the results of the 
validation included:
1) The determining of ATV by High Performance Liquid 
Chromatography coupled to a UV/DAD (HPLC/UV-
DAD) detector. 
·	 Intermediate precision and repeatability showed a 
relative standard deviation (RSD) of less than 4%.
·	 Intra-day and between-day accuracy presented aver-
age recovery percentages of 99.95% and 100.11%, 
respectively.
·	 Linearity was performed in the range from 17.5 to 
32.5 μg mL-1; the linear correlation coefficient (r) 
showed the value of 0.9993, which meets the re-
quirements pre-determined by RE 899/03 (greater 
than 0.99) (Brasil, 2003a).
·	 LOD and LOQ were 1.34 μg mL-1 and 4.06 mg mL-1, 
respectively, and were evaluated on the third linear 
curves, as required.
Specificity was evaluated after the drug had been 
subjected to conditions of stress, and the samples were 
then analyzed by HPLC. Figure 1 shows the chromato-
grams of the drug and samples after undergoing stress 
under acid and basic hydrolysis, exposure to dry heat, UV 
light exposure, neutral hydrolysis, and oxidation.
Considering the results, it could be observed that 
the drug showed a retention time (RT) of 3.517 minutes 
and that the drug presented degradation after undergoing 
stress caused by acidic and basic hydrolysis. It was also 
FIGURE 1 - ATV chromatogram before (bottom) and after stress conditions: neutral hydrolysis, acid hydrolysis, basic hydrolysis, 
oxidation, exposure to UV light, and exposure to temperature (dry heat).
noted that the peak of the sample submitted to oxidation 
with an RT of 3.0 minutes represented the peak of hydro-
gen peroxide.
The sample treated by acid hydrolysis showed par-
tial degradation with the formation of two degradation 
products, with RT = 4.440 and 4.853 minutes (Figure 
1). The specificity proved to be adequate, with resolu-
tion (Rs) between the peaks satisfactory. The resolution 
between ATV and the first degradation product (DP1) 
was 5.89, and between DP1 and the second degradation 
product (DP2) was 2.39, indicating a good separation 
between the peaks. The degradation in a basic medium 
can be observed by reducing the area corresponding to 
the drug.
Regarding the peak purity, which is a requirement 
for specificity, the Waters equipment mark indicates that 
a pure peak must have a value of Purity Angle < Purity 
Threshold to be considered pure. The ATV peak, in the 
presence of degradation products and under acid hydroly-
sis, showed a Purity Angle of 0.127 and a Purity Thresh-
old of 0.239. Figure 2 shows the spectra obtained by a 
UV/DAD detector at the beginning, on top, and at the end 
of the ATV peak for the sample when in the presence of 
degradation products, demonstrating the similarity among 
the spectra and confirming no coeluition.
The chromatographic performance was evaluated 
for the ATV peak, where the retention factor (k’) was 1.49, 
the tailing factor (T) was 1.3, and the number of theoretical 
plates (N) was 8601 plates/column. All parameters were 
in accordance with a chromatographic method.
The robustness was evaluated against three varia-
tions in chromatographic conditions, using a flow of 
1 mL min-1, a mobile phase ratio of 30:70, and the furnace 
turned off. The results proved to be satisfactory, with 
a difference of less than 1% of the content range in the 
analysis conditions.
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2) Determination of ATV by spectrophotometry in the UV 
region and lectures at 238 nm of samples diluted in water.
·	 Intermediate precision and repeatability showed an 
RSD of less than 4%.
·	 Intra-day and between-day accuracy presented aver-
age recovery percentages of 99.85% and 100.42%, 
respectively.
·	 Linearity was performed in the range 17.5 to 
32.5 μg mL-1, and the linear correlation coefficient 
(r) showed the value of 0.9963, which meets the 
requirements pre-determined by RE 899/03 (greater 
than 0.99) (Brasil, 2003a).
·	 LOD and LOQ were 3.01 μg mL-1 and 7.12 mg mL-1, 
respectively and were evaluated on the third linear 
curves, as required.
·	 Specificity was evaluated after the drug had been 
subjected to conditions of stress. This method 
proved to be unsatisfactory, since the degradation 
products resulting from the stress caused by an 
acidic medium interfered with the reading.
Given the results obtained by UV spectrophotometry 
and the absence of specificity of this method, when the 
ATV is diluted in an acid medium, a degradation of the 
drug can be observed. This method is suitable only when 
the ATV is diluted in water, producing satisfactory results 
for precision, accuracy, linearity, LOD, LOQ, and specific-
ity. Thus, UV spectrophotometry is a great alternative to 
being tested for dissolution in water, due to the advantages 
of cost and facility.
Development of dissolution test to compare 
formulations
According to RE 31/2010, to develop a dissolution 
test, the parameters to be set include: dissolution medium, 
pH, apparatus, rotation, use of anchors, use of surfactants, 
deaeration, and the choice of the dissolved amount (Q 
value). The suitable dissolution test should not be too little 
nor too great discriminatory, and it should be able to distin-
guish between good and bad formulations (Brasil, 2010b).
To perform evaluations and comparisons among 
pharmaceutical formulations, the analysis of the obtained 
ATV presented 99.82% of the labeled amount for refer-
ence product and 100.82% of the labeled amount for the 
generic product.
To choose the dissolution medium, the tests were not 
performed within the full range of physiological pH (1.2 
to 6.8), as recommended in the legislation. ATV presented 
problems because of the degradation caused by the acidic 
medium, as could be observed in the intrinsic stability 
study. Therefore, the present study chose to use water, 
together with the possible addition of surfactants. The 
addition of surfactants is justified by their low solubility 
(class II second BCS product). These were evaluated to 
determine the discriminatory power of the method. The 
usual rotation method with paddles and baskets was set 
to between 50 and 100 rpm, and then they were evaluated.
Table II shows the results found in the dissolution 
profile of the generic product and the investigated dissolu-
tion conditions (medium, rotation, and apparatus).
It can be observed in Table II that the addition of 
surfactants was not necessary, since the product showed 
a release (solubility) that was only suitable with water. 
The rotation speed of 75 rpm showed an adequate release 
with low RSD which presented a satisfactory second RE 
31/2010 resolution. The use of anchors was unnecessary 
because the pharmaceutical formulation did not fluctuate 
(Brasil, 2010b).
To complete the study of choice for dissolution con-
ditions, the reference drug product was evaluated using 
the optimal condition observed for the generic product, 
in which water was used as the dissolution medium and 
the rotation speed was 75 rpm (Condition III). However, 
according to the results, dissolution of greater than 90% 
could be observed within 5 minutes. Next, the test was 
performed at 50 rpm (Condition II), which also showed a 
rapid dissolution of the drug of up to 90% in 10 minutes. 
FIGURE 2 - Overlay of UV spectra of ATV at the beginning 
(RT = 3.436 min), on top (RT = 3.516 min), and at the end (RT 
= 3.616 min) of the ATV peak in the presence of degradation 
products, with their λmáx.
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TABLE II - Average amount of the dissolved active ingredient (Amount dissolved, %) and RSD (%) of the generic product under 
different conditions
Conditions
Time (minutes)
5 10 15 30 45 60
(I) Water + 0.4% SLS, Paddle, 50 rpm Average 27 49 67 107 116 113
RSD 17.6 22.8 25.2 5.3 1.9 1.7
(II) Water, Paddle, 50 rpm Average 15 25 34 52 66 81
RSD 35.4 18.3 26.2 18.6 17 15.3
(III) Water, Paddle, 75 rpm Average 33 59 87 105 112 114
RSD 13.9 17.9 9.9 9.6 1.8 1.9
TABLE III - Average amount of the dissolved active ingredient (Amount dissolved, %) and RSD (%) of the reference product under 
different conditions
Conditions
Time (minutes)
5 10 15 30 45 60
(II) Water, Paddle, 50 rpm Average 72 93 97 100 104 108
RSD 11 4.6 3.5 2.4 2.7 1.4
(III) Water, Paddle,75 rpm Average 91 104 109 111 113 113
RSD 7.5 0.9 1.1 0.8 2.4 0.8
(IV) Water, Basket, 50 rpm Average 27 34 40 49 57 69
RSD 30.2 23.6 20.6 17.6 15.2 16.6
In both cases, the RSD was adequate, below the limit, and 
lower than that of the generic product, which shows the 
homogeneity and quality of the reference product. The 
basket method was also evaluated for the reference prod-
uct. However, as the tablet weight is quite high, with large 
amounts of excipients, it commits the use of the basket, 
given that there was obstruction of the mesh, which can be 
confirmed through the results from the high value of RSD 
among samples at the same times. The use of anchors in 
conditions with paddle apparatus proved to be unnecessary 
because the formulation did not fluctuate.
Table III presents the results for the dissolution profile 
of the reference product and the conditions of the evaluated 
dissolution tests (medium, rotation, and apparatus).
To compare the F2 and the DE in percentage, the 
calculations were performed for conditions II and III, 
which showed the best results, since both RSD were lower 
than recommended.
Figure 3 shows the dissolution profile of pharmaceu-
tical products in conditions II and III, as well as the entire 
AUC, to calculate the DE percentage. 
The DE percentage was calculated for all samples, 
using the AUC as described in Figure 3 and considering 
that the dissolution of the area equivalent to 100% in 60 
minutes was 6000, as follows:
a) Reference Product, condition II = 92.41%
b) Generic Product, condition II = 48.62%
c) Reference Product, condition III = 95.08%
d) Generic Product, condition III = 84.66%
Statistical calculations were analyzed by ANOVA, 
with p<0.05, which were done for each sampling time 
between the two tested formulations. The critical F and 
the calculated F were compared in an attempt to determine 
the similarity between the points of the dissolution curve 
between the two formulations. Table IV shows the calcu-
lated F for each point. It can be seen that only at times of 
30, 45, and 60 minutes, under condition III, did the results 
show no statistically significant differences. Statistically 
significant differences could be observed when the calcu-
lated F was higher than the critical F of 4.30, considering 
a 5% significance.
It could be observed that in condition II (50 rpm) 
all results for reference and generic products presented 
statistically significant differences. In condition III (75 
rpm), a similarity in the results could be observed begin-
ning at 30 minutes, when the drug dissolution was 100% 
in both samples. However, in the ascending portion of the 
dissolution curve, which represents the initial point of 
dissolution, the results show a statistically significant dif-
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ference. The calculation of the F2 value is only important 
in the initial portion of the dissolution curve, which shows 
the dissolution kinetics. When the curve reaches the pla-
teau (maximum release of the drug), no variation between 
the points can be identified, thus showing no significant 
difference in the results in this range of rotation speed.
The formulation of both generic and reference prod-
ucts presents a combination of super-disintegrants and sur-
factants, which is consistent with the high solubility of the 
drugs in a few minutes, even in the Class II drugs. As the 
dissolution average was greater than 85% in 15 minutes, 
the impact on the reference product may be considered 
very rapid dissolution. As such, the evaluation of F2 loses 
its discriminative power and even becomes unsuitable for 
comparisons in pharmaceutical formulations.
In the F2 calculation, the legislation adopts the fol-
lowing criteria to select the sampling points: at least five 
sampling collections, only one of which may be at a point 
after both drugs reach 85% of dissolution. The determina-
tion of these points gives value to the ascending portion 
of the dissolution profile curve, thus making it possible 
to evaluate the pharmaceutical formulations with more 
distinct criteria (Brasil, 2010b).
When developing a new product containing ATV as 
an active ingredient, to compare it with the reference drug 
product, the ideal conditions to be used in the dissolution 
test would include condition II, using water as a dissolu-
tion medium and a paddle apparatus at a rotation speed of 
50 rpm, so as to be more discriminative in relation to the 
condition III, which uses the same dissolution medium, 
but with the paddle apparatus rotation speed set at 75 
rpm. Thus, the tolerance (Q) in the dissolution test can be 
defined as 80% (Q) at 15 minutes, which is the defining 
characteristic of a drug’s very rapid dissolution.
Although the generic product could be identified, 
in the test proposed in condition II (50 rpm), this product 
would not be considered pharmaceutically equivalent. 
However, as the manner in which the test was conducted 
by the manufacturing laboratory is unknown, since there 
is no pharmacopoeial monograph, the manufacturer may 
legally have chosen a less discriminatory condition to gain 
approval as a generic product. In addition, Bioequivalence 
results prevail over Equivalence results, and, despite a 
more rigorous control of the experiments using dissolu-
tion profiles, companies have used the supposed legality 
of these Bioequivalence results to formally register drugs.
CONCLUSIONS
The analytical method proposed in this study was 
able to generate reliable results, given that all parameters 
were satisfactory, allowing for the validation of method-
ologies.
The HPLC method was validated to determine the 
ATV content, which employs a reverse C18 column phase 
(250 x 4.6 mm 5 mm), a mobile phase containing 0.1% 
of phosphoric acid, and acetonitrile (35:65% v/v) with a 
flow of 1.5 mL.min-1 and detection at 238 nm. The HPLC 
method presented all the validation parameters according 
FIGURE 3 – Dissolution Profiles. a) – Reference product, 
condition II; b) – Generic product, condition II; c) Reference 
product, condition III; d) Generic product, condition III.
TABLE IV - F calculated in comparison to the dissolution 
in each time for the reference and generic products in both 
condition patterns 
  
Time (minutes) Condition II (water, 50 rpm)
Condition III 
(water, 75 rpm)
5 142.25 294.73
10 702.68 109.14
15 255.53 40.88
30 142.25 2.44
45 62.74 1.16
60 29.78 0.36
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to requirements, in addition to the performance param-
eters, producing a chromatographic retention factor (k’) of 
1.49, a tailing factor (T) of 1.3, and a number of theoretical 
plates (N) of 8,601 plates/column.
The validated method proposed by UV spectropho-
tometry, with dilution in water at 238 nm, should only be 
used for analysis in the dissolution test, as it presented 
limitations in specificity when there was an alteration in 
pH levels.
Since no official method currently exists to evaluate 
the dissolution test, a condition pattern was proposed for 
the evaluation of pharmaceutical formulations, used under 
the following conditions: water as a dissolution medium, 
1000 mL as a volume, paddle apparatus at a rotation speed 
of 50 rpm, 80% (Q) in 15 minutes with UV spectrophotom-
eter readings at 238 nm, using the standard concentration 
of 32.0 mg/mL under the same solvent.
Tablet formulations of ATV can be considered to 
be very rapid dissolutions, and therefore do not require 
the calculation of F2. In the condition proposed as the 
ideal method of dissolution, the generic product was not 
considered pharmaceutically equivalent. However, upon 
applying other less discriminative methods, but which also 
fall within legal parameters, these same generic products 
can be considered to be pharmaceutical equivalents.
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